Perrigo's 4th-qtr income climbs 6%
USA-based generic drug and health care product developer Perrigo says that net income the the fiscal fourth quarter ended June 30, 2007, increased 53% to $19.7 million, or $0.20 per share. The firm explained that the improvement had been stimulated by higher sales of its prescription drug products, which contributed $44.1 million, up 34%.
Fourth-quarter revenues totalled $374.3 million, up 5.4% on the year-earlier comparable period. Perrigo's Active Pharmaceutical Ingredients operations achieved growth of 25% reaching $33.6 million.
In addition, turnover from other operations, consisting of Israel Consumer Products, Israel Pharmaceutical and Diagnostic Products segments, grew 2.7% to $39.3 million. Conversely, the firm's consumer health operations saw sales drop $1.0 million to $257.3 million.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze